Autopsy report · NCT05177796

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

“0 participants recruited”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma

Interventions

Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel; Panitumumab; Pembrolizumab

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
  “0 participants enrolled” (84% match in meaning)
• FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer
  “No participants were recruited” (80% match in meaning)
• Delirium Incidence and Indwelling Urinary CathEterization After Acute Stroke
  “all participants recruited” (78% match in meaning)
• Endothelial Cell Gene Networks of CVD
  “No eligible participants were recruited” (74% match in meaning)
• Study of Sodium Bicarbonate in Restoring Blocked Catheters
  “No participants were enrolled” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.